2024
Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate risk
2010
The Effect of How Outcomes Are Framed on Decisions about Whether to Take Antihypertensive Medication: A Randomized Trial
Carling CL, Kristoffersen DT, Oxman AD, Flottorp S, Fretheim A, Schünemann HJ, Akl EA, Herrin J, MacKenzie TD, Montori VM. The Effect of How Outcomes Are Framed on Decisions about Whether to Take Antihypertensive Medication: A Randomized Trial. PLOS ONE 2010, 5: e9469. PMID: 20209127, PMCID: PMC2830888, DOI: 10.1371/journal.pone.0009469.Peer-Reviewed Original ResearchConceptsAntihypertensive medicationsVisual analog scaleCardiovascular diseaseVAS scoresRelative importance scoresCVD risk reductionYear old manLow baseline riskDetailed patient informationRandomized trialsAnalog scaleRisk factorsBaseline riskMedicationsAdult volunteersHypertensionLogistic regressionPatient informationSignificant decreaseTrialsSignificant differencesRisk reductionPresentationParticipantsRisk
2006
Effect of Door-to-Balloon Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction
McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, Peterson ED, Blaney M, Frederick PD, Krumholz HM, Investigators N. Effect of Door-to-Balloon Time on Mortality in Patients With ST-Segment Elevation Myocardial Infarction. Journal Of The American College Of Cardiology 2006, 47: 2180-2186. PMID: 16750682, DOI: 10.1016/j.jacc.2005.12.072.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionST-segment elevation myocardial infarctionBalloon timeElevation myocardial infarctionSymptom onsetMyocardial infarctionHospital mortalityPatient characteristicsDoor timeEffect of doorPrimary PCIBaseline risk statusPercutaneous coronary interventionHigh-risk factorsSTEMI patientsCohort studyCoronary interventionLonger doorEntire cohortSubgroup analysisNational registryBaseline riskMortality riskPatientsMortality